# David Tamborero

## List of Publications by Year
## in descending order

| | | | |
|---|---|---|---|
| **63** papers | **12,253** citations | 109137<br>**35** h-index | 110170<br>**64** g-index |
| **71** all docs | **71** docs citations | **71** times ranked | **22353** citing authors |

| # | ARTICLE | IF | CITATIONS |
|---|---------|-----|-----------|
| 1 | Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell, 2018, 173, 371-385.e18. | 13.5 | 1,670 |
| 2 | A Landscape of Pharmacogenomic Interactions in Cancer. Cell, 2016, 166, 740-754. | 13.5 | 1,518 |
| 3 | Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 2014, 158, 929-944. | 13.5 | 1,242 |
| 4 | Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nature Genetics, 2015, 47, 106-114. | 9.4 | 830 |
| 5 | Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2015, 526, 519-524. | 13.7 | 749 |
| 6 | IntOGen-mutations identifies cancer drivers across tumor types. Nature Methods, 2013, 10, 1081-1082. | 9.0 | 517 |
| 7 | CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nature Genetics, 2017, 49, 170-174. | 9.4 | 460 |
| 8 | Comprehensive identification of mutational cancer driver genes across 12 tumor types. Scientific Reports, 2013, 3, 2650. | 1.6 | 437 |
| 9 | Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature, 2020, 578, 102-111. | 13.7 | 424 |
| 10 | OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics, 2013, 29, 2238-2244. | 1.8 | 397 |
| 11 | Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations. Genome Medicine, 2018, 10, 25. | 3.6 | 366 |
| 12 | Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. European Heart Journal, 2007, 28, 836-841. | 1.0 | 351 |
| 13 | In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities. Cancer Cell, 2015, 27, 382-396. | 7.7 | 290 |
| 14 | A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. Clinical Cancer Research, 2018, 24, 3717-3728. | 3.2 | 267 |
| 15 | Gender Differences in Clinical Manifestations of Brugada Syndrome. Journal of the American College of Cardiology, 2008, 52, 1567-1573. | 1.2 | 265 |
| 16 | Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace, 2008, 10, 15-20. | 0.7 | 237 |
| 17 | Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Research, 2014, 24, 212-226. | 2.4 | 175 |
| 18 | Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace, 2010, 12, 1084-1089. | 0.7 | 138 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 19 | Left Atrial Posterior Wall Isolation Does Not Improve the Outcome of Circumferential Pulmonary Vein Ablation for Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 35-40. | 2.1 | 129 |
| 20 | Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace, 2010, 12, 30-36. | 0.7 | 109 |
| 21 | Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. European Heart Journal, 2009, 30, 1880-1884. | 1.0 | 104 |
| 22 | A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer. Nature Genetics, 2020, 52, 448-457. | 9.4 | 104 |
| 23 | JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML. Blood, 2017, 130, 789-802. | 0.6 | 90 |
| 24 | Optimizing the Programation of Cardiac Resynchronization Therapy Devices in Patients With Heart Failure and Left Bundle Branch Block. American Journal of Cardiology, 2007, 100, 1002-1006. | 0.7 | 84 |
| 25 | Comparison of Benefits and Mortality in Cardiac Resynchronization Therapy in Patients With Atrial Fibrillation Versus Patients in Sinus Rhythm (Results of the Spanish Atrial Fibrillation and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 | 0.7 | 80 |
| 26 | Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace, 2010, 12, 24-29. | 0.7 | 73 |
| 27 | Comparison of algorithms for the detection of cancer drivers at subgene resolution. Nature Methods, 2017, 14, 782-788. | 9.0 | 72 |
| 28 | Fate of Left Atrial Function as Determined by Real-Time Three-Dimensional Echocardiography Study After Radiofrequency Catheter Ablation for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2008, 101, 1285-1290. | 0.7 | 58 |
| 29 | Electrocardiographic Optimization of Interventricular Delay in Cardiac Resynchronization Therapy: A Simple Method to Optimize the Device. Journal of Cardiovascular Electrophysiology, 2007, 18, 1252-1257. | 0.8 | 57 |
| 30 | Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nature Medicine, 2020, 26, 992-994. | 15.2 | 56 |
| 31 | OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action. Bioinformatics, 2014, 30, i549-i555. | 1.8 | 49 |
| 32 | Electrocardiographic versus Echocardiographic Optimization of the Interventricular Pacing Delay in Patients Undergoing Cardiac Resynchronization Therapy. Journal of Cardiovascular Electrophysiology, 2011, 22, 1129-1134. | 0.8 | 48 |
| 33 | Left Atrial Contractility is Preserved After Successful Circumferential Pulmonary Vein Ablation in Patients with Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2008, 19, 374-379. | 0.8 | 47 |
| 34 | Midterm 'super-response' to cardiac resynchronization therapy by biventricular pacing with fusion: insights from electro-anatomical mapping. Europace, 2009, 11, 1675-1682. | 0.7 | 47 |
| 35 | The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nature Cancer, 2022, 3, 251-261. | 5.7 | 44 |
| 36 | Incidence of Pulmonary Vein Stenosis in Patients Submitted to Atrial Fibrillation Ablation: A Comparison of the Selective Segmental Ostial Ablation vs the Circumferential Pulmonary Veins Ablation. Journal of Interventional Cardiac Electrophysiology, 2005, 14, 21-25. | 0.6 | 40 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 37 | Optimization of the Interventricular Delay in Cardiac Resynchronization Therapy Using the QRS Width. American Journal of Cardiology, 2009, 104, 1407-1412. | 0.7 | 39 |
| 38 | Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Cancer, 2021, 2, 1224-1242. | 5.7 | 37 |
| 39 | Fast randomization of large genomic datasets while preserving alteration counts. Bioinformatics, 2014, 30, i617-i623. | 1.8 | 36 |
| 40 | Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget, 2017, 8, 56338-56350. | 0.8 | 35 |
| 41 | Anodal Capture in Cardiac Resynchronization Therapy Implications for Device Programming. PACE - Pacing and Clinical Electrophysiology, 2006, 29, 940-945. | 0.5 | 34 |
| 42 | Relation of Response to Cardiac Resynchronization Therapy to Left Ventricular Reverse Remodeling. American Journal of Cardiology, 2006, 97, 876-881. | 0.7 | 32 |
| 43 | Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacological treatment. Europace, 2010, 12, 1136-1140. | 0.7 | 31 |
| 44 | Six-minute walking test predicts long-term cardiac death in patients who received cardiac resynchronization therapy. Europace, 2009, 11, 338-342. | 0.7 | 30 |
| 45 | Usefulness of Ventricular Dyssynchrony Measured Using M-Mode Echocardiography to Predict Response to Resynchronization Therapy. American Journal of Cardiology, 2007, 100, 84-89. | 0.7 | 29 |
| 46 | Circumferential pulmonary vein ablation: Does use of a circular mapping catheter improve results? A prospective randomized study. Heart Rhythm, 2010, 7, 612-618. | 0.3 | 29 |
| 47 | Oncodrive-CIS: A Method to Reveal Likely Driver Genes Based on the Impact of Their Copy Number Changes on Expression. PLoS ONE, 2013, 8, e55489. | 1.1 | 29 |
| 48 | Is there an anatomical substrate for idiopathic paroxysmal atrial fibrillation? A case–control echocardiographic study. Europace, 2007, 9, 294-298. | 0.7 | 27 |
| 49 | Effect of Repeated Radiofrequency Catheter Ablation on Left Atrial Function for the Treatment of Atrial Fibrillation. American Journal of Cardiology, 2011, 108, 1741-1746. | 0.7 | 27 |
| 50 | Predictors of arrhythmia recurrence in patients with lone atrial fibrillation. Europace, 2007, 10, 9-14. | 0.7 | 23 |
| 51 | Cooled-tip vs. 8 mm-tip catheter for circumferential pulmonary vein ablation: comparison of efficacy, safety, and lesion extension. Europace, 2008, 10, 955-960. | 0.7 | 18 |
| 52 | Plasma tissue inhibitor of matrix metalloproteinase–1 (TIMP–1): an independent predictor of poor response to cardiac resynchronization therapy. European Journal of Heart Failure, 2010, 12, 492-498. | 2.9 | 16 |
| 53 | CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. Leukemia, 2019, 33, 518-558. | 3.3 | 15 |
| 54 | Comparison of Hemodynamic versus Dyssynchrony Assessment for Interventricular Delay Optimization with Echocardiography in Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 984-990. | 0.5 | 9 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 55 | Noninvasive Evaluation of Radiofrequency Lesions in the Human Ventricular Myocardium by Contrast-Enhanced Cardiac Magnetic Resonance. Circulation: Arrhythmia and Electrophysiology, 2009, 2, 208-211. | 2.1 | 7 |
| 56 | Cardiac Motion Estimation from Intracardiac Electrical Mapping Data: Identifying a Septal Flash in Heart Failure. Lecture Notes in Computer Science, 2009, , 21-29. | 1.0 | 7 |
| 57 | Selective segmental ostial ablation and circumferential pulmonary veins ablation. Results of an individualized strategy to cure refractory atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2007, 19, 19-27. | 0.6 | 6 |
| 58 | Rational design of cancer gene panels with OncoPaD. Genome Medicine, 2016, 8, 98. | 3.6 | 5 |
| 59 | Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. Blood, 2014, 124, 2046-2046. | 0.6 | 3 |
| 60 | Electrocardiographic Optimization of Cardiac Resynchronization Devices: Simple, but Not So Simple!. American Journal of Cardiology, 2009, 103, 894. | 0.7 | 2 |
| 61 | Electrocardiographic optimization of interventricular delay in cardiac resynchronization therapy: Correlation with echocardiography. Heart Rhythm, 2005, 2, S289. | 0.3 | 1 |
| 62 | Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma. JCO Precision Oncology, 2021, 5, 974-980. | 1.5 | 1 |
| 63 | Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response. Blood, 2014, 124, 3351-3351. | 0.6 | 0 |